A Pennsylvania federal judge on Friday suspended a false advertising suit by GlaxoSmithKline LLC against Teva Pharmaceuticals USA Inc. over Teva's marketing of its generic Wellbutrin as equivalent to the brand-name drug, though another similar suit is going forward. GSK is represented by Jason A. Leckerman of Ballard Spahr LLP.

Related Practice